Skip to main content
LIFECORE BIOMEDICAL, INC. \DE\ logo

LIFECORE BIOMEDICAL, INC. \DE\ — Investor Relations & Filings

Ticker · LFCR ISIN · US5147661046 LEI · 549300EHBZ5OM9ND9O43 US Manufacturing
Open in API
Filings indexed 1,096 across all filing types
Latest filing 2011-01-28 Major Shareholding Noti…
Country US United States of America
Listing US LFCR

About LIFECORE BIOMEDICAL, INC. \DE\

https://www.lifecore.com/

Lifecore Biomedical is an integrated contract development and manufacturing organization (CDMO) that specializes in sterile injectable pharmaceutical drug products and medical devices. The company provides a full range of services, including specialty formulation, process development, aseptic filling, and final packaging, supporting products from clinical phases through to commercial supply. A key area of expertise is the handling of complex and highly viscous formulations. In addition to its CDMO capabilities, Lifecore is a primary producer of non-animal-sourced sodium hyaluronate (hyaluronic acid), offering it in various molecular weights and formats, including bulk material, hydrogels, and filled syringes and vials for diverse applications.

Recent filings

Filing Released Lang Actions
SC 13G Filing
Major Shareholding Notification
2011-01-28 English
10-Q Filing
Interim / Quarterly Report Q2 2011
2011-01-06 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 4, 2011, by Landec Corporation. It announces the issuance of a press release reporting the company's consolidated financial results for the second quarter of fiscal year 2011 ended November 28, 2010. The text states that the press release is attached as Exhibit 99.1 and is incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of financial results via a press release. The length of the document is 3048 characters, which is relatively short and consistent with an announcement rather than a full earnings release. According to the classification rules, initial announcements of quarterly financial results in a press release format are classified as Earnings Release (ER). Therefore, this document should be classified as an Earnings Release (ER).
2011-01-04 English
8-K Filing
Capital/Financing Update Classification · 90% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it contains a press release providing revised guidance for fiscal year 2011 revenue and net income growth. It explicitly states that the information is being furnished and not filed, and includes a press release as an exhibit. The content is an update on financial expectations rather than a full earnings release or detailed financial report. Given the nature of the document as a current report announcing a financial update and guidance revision, it fits best under the category Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including financial guidance updates. The document length is short (2903 characters), and it is not a full financial report or earnings release. Therefore, the classification is CAP with high confidence.
2010-12-14 English
4 Filing
Director's Dealing
2010-12-13 English
4 Filing
Director's Dealing
2010-11-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.